NasdaqGM:IRONBiotechs
Disc Medicine (IRON): Reassessing Valuation After Encouraging RALLY-MF Phase 2 Anemia Data
Early Trial Data Puts Disc Medicine In Focus
Disc Medicine (IRON) just put its RALLY-MF Phase 2 data for DISC-0974 on the table, showing meaningful anemia improvements in myelofibrosis patients that could reshape expectations around this small hematology focused pipeline.
See our latest analysis for Disc Medicine.
The news lands with Disc already in a strong groove, with a roughly 53% 3 month share price return and a 42.65% 1 year total shareholder return hinting that momentum is building...